New drug KINE-101 tested for Tough-to-Treat nerve disorder
NCT ID NCT07343310
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tested a single dose of a new drug called KINE-101 in 9 adults with chronic inflammatory demyelinating polyneuropathy (CIDP) that hadn't improved with steroids. The main goal was to check if the drug is safe and tolerable. Researchers also looked at whether it might help with symptoms like muscle strength and disability, but the study was too small to draw firm conclusions.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
KINE-101 injection
What this could lead to
If safe, this could point toward a new treatment option for people with CIDP who don't respond to standard steroid therapy.
What could go wrong
This is a very early, small Phase 1 trial with only 9 participants. The main goal is safety, not effectiveness, and the drug may not work or could have side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CIDP - CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Kangbuk Samsung Hospital
Seoul, Seoul, 03181, South Korea
-
Samsung Medical Center
Seoul, Seoul, 06351, South Korea